Issue #3 of Rheuminate is now out! We highlight new data on the long-term safety and efficacy of upadacitinib in RA, feature the autoimmune disease-related subset of the INBUILD trial in ILD with nintedanib, and review the impact of adding a multidisciplinary care billing code on access to rheumatology care in British Columbia.

Rheuminate is a monthly selection of new publications clinically relevant to the SMART community of Canadian rheumatologists.

In this third issue, we consider the following topics:

  • Long-term extension data for UPA vs ADA in RA
  • Nintedanib for autoimmune disease-related interstitial lung disease
  • Multidisciplinary care assessments at rheumatology clinics in BC

>> Read Rheuminate Issue #3 here.

View all issues of Rheuminate online at smartrheum.org/rheuminate